Monash University

Embargoed and Restricted Access

Reason: Under embargo until May 2025. After this date a copy can be supplied under Section 51(2) of the Australian Copyright Act 1968 by submitting a document delivery request through your library, or by emailing

Elucidating the molecular regulation of the dendritic cell receptor, Clec9A

posted on 2022-05-11, 04:25 authored by NICOLE MICHAEL
Dendritic cells are the immune cells critical in vaccination as they sense danger and initiate immunity. Clec9A is a Dendritic cell receptor that is the target for novel vaccine technologies that enhance immunity to cancers and viruses. Our research identified a novel regulatory pathway for Clec9A. Clec9A interacts with other proteins, namely RNF41, ERLIN1/2 and TMEM59. ERLIN/2 and RNF41 promote the degradation of Clec9A, while TMEM59 enhances the display of Clec9A at the dendritic cell surface potentially to enhance Clec9A-mediated immune responses. These novel pathways may ultimately be exploited to enhance Clec9A-based vaccines and promote immunity to cancer.


Principal supervisor

Mireille Hanna Lahoud

Additional supervisor 1

Mark Wright

Year of Award


Department, School or Centre

Biomedical Sciences (Monash Biomedicine Discovery Institute)

Additional Institution or Organisation

Biochemistry and Molecular Biology

Campus location



Doctor of Philosophy

Degree Type



Faculty of Medicine, Nursing and Health Sciences